NMS·Healthcare·$378M·#309 / 520 in Healthcare
PRLD Prelude Therapeutics Incorporat
38HIGH RISK
CATEGORY BREAKDOWN
GROWTH89
QUALITY0
STABILITY38
VALUATION0
GOVERNANCE57
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+73.4%
89
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
8 months
18
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
25.9%
79
< 25% strong
Price / Sales
Market cap relative to trailing revenue
31.1x
0
< 3x strong
Rule of 40
Growth rate plus operating margin
-788
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
13.8%
73
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+15.0%
25
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE PRLD WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when PRLD's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.